Engineered gut bacteria improves type 1 diabetes in mice

04/10/2012 | Genetic Engineering & Biotechnology News

Lactococcus lactis that was engineered to secrete whole proinsulin autoantigen and immunomodulatory human cytokine IL-10 stabilized blood glucose levels and suppressed diabetes-related autoantigen responses when fed to non-obese mice with type 1 diabetes, according to a study in the Journal of Clinical Investigation. L. lactis-anti-CD3 therapy appeared to reactivate beta cells and may only be successful when there is an adequate number of potentially functional cells, researchers said.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT